GLP‑1 drugs may fight addiction across every major substance, according to a study of 600,000 people / Medical Express

medicalxpress - A patient of mine, a veteran who had tried to quit smoking for over a decade, told me that after he started a GLP-1 drug for his diabetes, he lost interest in cigarettes. He didn't use a patch. He didn't set a quit date. He simply lost interest. It happen…

4 days / oncodaily

GLP‑1 drugs may fight addiction across every major substance, according to a study of 600,000 people

6 days / medicalxpress

GLP-1 drugs tied to lower addiction risk: Study

6 days / beckershospitalreview / Ella Jeffries

GLP‑1 drugs like Ozempic may lower the risk of addiction: New study

6 days / medicalxpress

Friday, March 6, 2026, 12:23 pm / permalink 20276 / 8 stories in 4 days

Novo Nordisk inks $2.1B oral obesity drug deal / Beckers

Ella Jeffries / beckershospitalreview - Novo Nordisk has partnered with Vivtex Corp. to develop next-generation oral biologic medicines for obesity, diabetes and related conditions. Under the agreement, Vivtex will license its proprietary oral drug-delivery technologies to Novo Nordisk and is e…

#obesity #healthcare #pharmaceuticals #novonordisk #weightloss #biotech #drugdevelopment #healthcarefinance

Pfizer gets obesity drug approval in China shortly after buying local rights

5 days / endpoints / Elizabeth Cairns

Trial suggests GLP-1 combo therapy cuts fat while preserving muscle in obesity

5 days / medicalxpress

Roche partner Zealand posts Phase 2 data for amylin obesity drug

5 days / endpoints / Kyle LaHucik

Novo Nordisk details Irish expansion; EuroAPI’s challenges continue

6 days / endpoints / Anna Brown

What to know about how GLP-1 medications might fight addiction

6 days / medicalxpress

Twenty percent of eligible youth prescribed GLP-1 receptor agonists

6 days / medicalxpress

GLP-1 medications get at the heart of addiction, study finds

6 days / medicalxpress

Quitting GLP-1 drugs triggers rapid regain, but 25% of weight loss may last

6 days / medicalxpress

Eli Lilly launches its direct-to-employer platform for obesity drugs

6 days / fiercehealthcare

Most Patients Keep Weight Off With Fewer GLP-1 Shots, Study Finds

6 days / nytimes / Roni Caryn Rabin

AHA urges HHS to block Novo Nordisk’s 340B data demand

6 days / beckershospitalreview / Paige Twenter

FDA sends Novo Nordisk 2nd warning over GLP-1 ads

6 days / beckershospitalreview / Erica Cerutti

How gut bacteria and diet can reprogram fat to burn more energy

7 days / medicalxpress

No more weekly injections? How lettuce cells could deliver GLP-1 pills

7 days / medicalxpress

GLP-1 weight-loss drugs comparably effective across age, race and starting weight

7 days / medicalxpress

FDA ramps up crackdown on GLP-1 drug compounding with fresh batch of 30 warning letters

7 days / fiercehealthcare

FDA warns 30 telehealth firms over compounded GLP-1 claims

7 days / beckershospitalreview / Ella Jeffries

Hims partner Strive Pharmacy will reintroduce GLP-1 pill pulled from market

8 days / endpoints / Shelby Livingston

Novo Nordisk inks $2.1B oral obesity drug deal

9 days / beckershospitalreview / Ella Jeffries

Novo Nordisk Commits Up to $2B to Drug Delivery Startup Vivtex for R&D of Oral Metabolic Meds

13 days / medcitynews / Frank Vinluan

Novo Nordisk teams with Langer-founded biotech for oral obesity drugs

14 days / endpoints / Kyle LaHucik

Tuesday, March 3, 2026, 1:22 am / permalink 20039 / 21 stories in 8 days

Novo Nordisk’s CagriSema beaten by Lilly’s Zepbound in head-to-head obesity trial / Endpoints

Elizabeth Cairns / endpoints - Novo Nordisk’s GLP-1/amylin combo drug CagriSema was not as good as Eli Lilly’s marketed obesity shot Zepbound in a head-to-head study, the Danish company said Monday. Patients in the REDEFINE 4 ...

#obesity #healthcare #pharmaceuticals #elililly #novonordisk #weightloss #drugdevelopment

GoodRx Launches Employer Program to Help Subsidize High-Cost Brand Drugs

10 days / medcitynews / Marissa Plescia

GLP-1 news galore; Top 100 venture investors; Doug Ingram to step down; and more

11 days / endpoints / Nicole DeFeudis

Walgreens Introduces Virtual Weight Management Offering

11 days / medcitynews / Marissa Plescia

Walgreens debuts virtual weight management clinic with access to GLP-1 meds

11 days / fiercehealthcare

Understanding GLP-1 signaling: A path to better therapies

12 days / medicalxpress

Novo Nordisk’s ‘strategic conundrum’: How being anchored to the past could cost it the future

12 days / endpoints / Elizabeth Cairns

Walgreens launches $49 virtual weight management visits

12 days / beckershospitalreview / Ella Jeffries

Lilly's GLP-1 pill beats Novo’s in diabetes trial, has more side effects

13 days / endpoints / Elizabeth Cairns

New GLP-1 pill orforglipron outperforms oral semaglutide in yearlong diabetes trial

13 days / medicalxpress

Annie Wong: Transforming Melanoma and Cancer Care Through the 2026 Lea Medal

15 days / oncodaily

Zepbound beats Novo Nordisk’s experimental GLP-1 in head-to-head trial

15 days / beckershospitalreview / Paige Twenter

Novo Nordisk’s CagriSema beaten by Lilly’s Zepbound in head-to-head obesity trial

16 days / endpoints / Elizabeth Cairns

Thursday, February 26, 2026, 7:23 am / permalink 19788 / 12 stories in 13 days

Novo Nordisk vows legal action to protect Wegovy pill / Medical Express

medicalxpress - Novo Nordisk said Thursday it would take legal action against a US chain offering a copycat of the new pill version of its Wegovy weight-loss drug.

#obesity #healthcare #pharmaceuticals #drugpricing #novonordisk #weightloss #drugdevelopment #digitalhealth

Novo Nordisk to expand Irish factory for Wegovy pill

26 days / endpoints / Anna Brown

Blockbuster weight loss drugs like Ozempic deliver big results but face big questions

28 days / sciencedaily

Why people won't quit a weight loss drug, even when it makes them feel sick

28 days / medicalxpress

FDA to Novo Nordisk: Correct ‘misleading’ GLP-1 pill TV ad

28 days / beckershospitalreview / Erica Cerutti

The fallout from Novo vs. Hims

29 days / endpoints / Lydia Ramsey Pflanzer

Hims pulls cheaper Wegovy pill after federal scrutiny

29 days / medicalxpress

Hims retreats from weight loss pill launch as Novo, FDA pressure mounts

4 wks / fiercehealthcare

After industry pressure, Hims & Hers stops selling Wegovy pill

4 wks / beckershospitalreview / Paige Twenter

Novo Nordisk sues Hims over Wegovy patent infringement, considers seeking 'hundreds of millions' in damages

4 wks / endpoints / Elizabeth Cairns

'Weight-loss jab helped me find my cancer'

4 wks / bbc

Hims & Hers Withdraws Knockoff Weight-Loss Pill After Regulatory Scrutiny

4 wks / nytimes / Rebecca Robbins

Hims says it will stop selling GLP-1 pill, after legal pressure from US

4 wks / endpoints / Drew Armstrong

The Hims vs. Novo showdown; Pfizer’s monthly GLP-1 data; Q4 earnings roundup; and more

4 wks / endpoints / Max Gelman

US calls for DOJ investigation of Hims over GLP-1 drugs

4 wks / endpoints / Shelby Livingston

Synergizing global clinical trials data: GLP-1 receptor agonist safety and novel clinical applications

4 wks / medicalxpress

FDA's Makary pledges crackdown on mass marketing of 'illegal copycat drugs' in wake of Hims' Wegovy pill push

4 wks / fiercehealthcare

FDA chief Makary takes aim at Hims' compounded Wegovy pill plans

4 wks / endpoints / Max Bayer

Novo's threat to sue Hims over Wegovy pill faces legal hurdle

4 wks / endpoints / Shelby Livingston

War breaks out over GLP-1 pills

4 wks / beckershospitalreview / Paige Twenter

Novo Nordisk vows legal action to protect Wegovy pill

4 wks / medicalxpress

Him & Hers plans to offer cheaper version of Wegovy pill, prompting Novo Nordisk to threaten legal action

4 wks / fiercehealthcare

Telehealth provider Hims goes after Novo's weight-loss pill with compounded version

4 wks / endpoints / Zachary Brennan

Thursday, February 5, 2026, 3:23 pm / permalink 18807 / 22 stories in 4 wks

Compounding pharmacy sues Eli Lilly, Novo Nordisk over GLP-1 access / Beckers

Ella Jeffries / beckershospitalreview - Strive Compounding Pharmacy filed a federal antitrust lawsuit Jan. 14 against Eli Lilly and Novo Nordisk, alleging the two drugmakers used their market power to restrict access to compounded GLP-1 medications and suppress competition. The lawsuit, filed i…

#obesity #healthcare #pharmaceuticals #drugpricing #elililly #novonordisk #weightloss #publichealth #biotech

Stephen Liu: What GLP-1 Therapies May Mean for Cancer Risk

7 wks / oncodaily

#JPM26: Sandoz CEO on Ozempic generic launch plans for 2026

7 wks / endpoints / Andrew Dunn

A compounding pharmacy hits back at Eli Lilly, Novo Nordisk with antitrust lawsuit

7 wks / endpoints / Shelby Livingston

Compounding pharmacy sues Eli Lilly, Novo Nordisk over GLP-1 access

7 wks / beckershospitalreview / Ella Jeffries

Thursday, January 15, 2026, 1:23 pm / permalink 17926 / 4 stories in 7 wks

FDA moves to remove suicide warnings from GLP-1 weight loss drugs / Medical Express

medicalxpress - Federal health regulators say popular weight loss drugs like Wegovy and Zepbound do not increase the risk of suicidal thoughts, and they have asked drugmakers to remove those warnings from medication labels.

#obesity #healthcare #pharmaceuticals #elililly #novonordisk #weightloss #publichealth #governmentpolicy #fda

Physician-Journalist Shines Light on Measles Upsurge and New GLP-1 Study

7 wks / kffhealthnews

What Merck’s Chief Medical Officer Thinks of Lilly’s Approach to GLP-1s

7 wks / medcitynews / Arundhati Parmar

Long-term GLP-1 use trims medical cost growth: Aon

7 wks / beckershospitalreview / Elizabeth Casolo

GLP-1s tied to improved survival in colorectal cancer

7 wks / beckershospitalreview / Paige Twenter

FDA moves to remove suicide warnings from GLP-1 weight loss drugs

7 wks / medicalxpress

Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial

7 wks / nature / Atul Malhotra

FDA moves to strike suicide risk warnings from 3 GLP-1s

1 month / beckershospitalreview / Ella Jeffries

FDA asks Lilly, Novo to remove suicide warnings from GLP-1 labels

1 month / endpoints / Zachary Brennan

Thursday, January 15, 2026, 1:23 pm / permalink 17924 / 8 stories in 7 wks

Novo Nordisk’s Wegovy Pill Becomes First FDA-Approved Oral GLP-1 Drug for Weight Loss / MedCity

Frank Vinluan / medcitynews - Beyond weight reduction and long-term maintenance of weight loss, the FDA decision for oral Wegovy covers use of the once-daily pill for reducing the risk of major cardiovascular events. Novo Nordisk expects the Wegovy tablet will launch in early January.…

#obesity #healthcare #pharmaceuticals #novonordisk #weightloss #drugdevelopment #fda

People who come off slimming jabs regain weight four times faster than dieters

2 months / bbc

Lack of support for people on weight loss drugs leaves them vulnerable to nutritional deficiencies, say experts

2 months / medicalxpress

Poll shows most Americans want to slim down

2 months / medicalxpress

In the UK, 1.6 million adults used weight loss drugs in the past year

2 months / medicalxpress

J.P. Morgan Report: Obesity & Diabetes Dealmaking Set a New Record in 2025

2 months / medcitynews / Frank Vinluan

Weight regain seems to occur within 2 years of stopping obesity drugs

2 months / newscientist

Stopping weight loss drugs linked to weight regain and reversal of heart health markers

2 months / medicalxpress

Ochsner launches program to cut GLP-1 costs

2 months / beckershospitalreview / Ella Jeffries

Ozempic, Wegovy might lower colon cancer risk

2 months / medicalxpress

The GLP-1 Revolution: Medical Aesthetics And The Coming Battle For Control

2 months / medcitynews / Chris Plance

The Weight Loss Market in 2026: 3 Questions That Will Shape the Next Decade

2 months / medcitynews / Shantanu Gaur

MASLD as a complication of obesity must include liver risk stratification

2 months / nature / Mary E. Rinella

Clarification of evidence selection for the framework for the pharmacological treatment of obesity and its complications from the EASO

2 months / nature / Andreea Ciudin

Novo Nordisk launches daily weight-loss pill to expand GLP-1 access

2 months / medicalxpress

Lilly goes back to Nimbus for an oral obesity drug in $55M deal

2 months / endpoints / Kyle LaHucik

Arrowhead’s RNAi obesity programs head to Phase 2 after encouraging early data

2 months / endpoints / Elizabeth Cairns

Older Americans Quit Weight-Loss Drugs in Droves

2 months / kffhealthnews / Paula Span

What is 'oatzempic'? Does it actually work for weight loss?

2 months / medicalxpress

Wegovy pill hits market at $299 per month

2 months / beckershospitalreview / Paige Twenter

GLP-1 drugs might help quell sleep apnea, study suggests

2 months / medicalxpress

Semaglutide may lower burden of hospitalizations in high-risk patients

2 months / medicalxpress

Novo Nordisk launches Wegovy pill at $25 per month for insured patients, $149 cash

2 months / endpoints / Elizabeth Cairns

PHTI: How Employers Can Manage GLP-1 Coverage

2 months / medcitynews / Marissa Plescia

What if Less Can Be More? A New Approach to GLP-1 Weight Loss Medications

2 months / medcitynews / Myra Ahmad

The expanding landscape of GLP-1 medicines

2 months / nature / Daniel J. Drucker

Multi-omic definition of metabolic obesity through adipose tissue–microbiome interactions

2 months / nature / Rima M. Chakaroun

What's ahead for the weight-loss drugs known as GLP-1s in 2026

2 months / npr / Sydney Lupkin

6 recent updates on GLP-1 drugs

2 months / beckershospitalreview / Ella Jeffries

CMS unveils Medicare coverage model for weight loss drugs

2 months / endpoints / Alexis Kramer

Brian Slomovitz: GLP-1 Receptor Agonists Are Changing the World

2 months / oncodaily

Toufic Kachaamy: A Major Shift in Obesity Treatment Just Happened

2 months / oncodaily

CMS launching payment model to boost access to GLP-1s in Medicaid, Part D

2 months / fiercehealthcare

CMS shares GLP-1 model: 7 notes

2 months / beckershospitalreview / Elizabeth Casolo

Novo Nordisk’s Wegovy Pill Becomes First FDA-Approved Oral GLP-1 Drug for Weight Loss

2 months / medcitynews / Frank Vinluan

Novo Nordisk says US approves first GLP-1 pill for weight loss

2 months / medicalxpress

Novo Nordisk eyes a strong launch with FDA approval of obesity pill

2 months / endpoints / Elizabeth Cairns

Tuesday, December 23, 2025, 3:22 pm / permalink 17254 / 36 stories in 2 months

Novo submits high-dose Wegovy for FDA approval using voucher / Endpoints

Max Bayer / endpoints - Novo Nordisk submitted a higher dose of its obesity drug Wegovy for FDA approval and is using a recently-won voucher to expedite the review. The company said Wednesday that it submitted ...

#obesity #healthcare #pharmaceuticals #novonordisk #weightloss #publichealth #biotech #drugdevelopment #fda

Novo Nordisk seeks FDA approval of higher-dose Wegovy

3 months / beckershospitalreview / Paige Twenter

Novo submits high-dose Wegovy for FDA approval using voucher

3 months / endpoints / Max Bayer

Saturday, November 29, 2025, 5:21 pm / permalink 16400 / 2 stories in 3 months

Novo Nordisk GLP-1 fails to slow Alzheimer’s in trials / Beckers

Ella Jeffries / beckershospitalreview - Novo Nordisk’s GLP-1 drug semaglutide did not demonstrate a statistically significant effect in slowing progression of Alzheimer’s disease in two late-stage clinical trials. According to a Nov. 24 news release from the company, two double-blinded, placebo…

#obesity #healthcare #pharmaceuticals #novonordisk #weightloss #publichealth #biotech #drugdevelopment

CMS unveils negotiated prices for Ozempic, Wegovy and other drugs from second round of IRA talks

3 months / endpoints / Nicole DeFeudis

Postpartum Prescription of GLP-1 Drugs Has Increased Sharply, Study Finds

3 months / nytimes / Roni Caryn Rabin

Novo Nordisk GLP-1 fails to slow Alzheimer’s in trials

3 months / beckershospitalreview / Ella Jeffries

Pill form of semaglutide fails to slow Alzheimer's in large trial

3 months / medicalxpress

Ozempic Drug Fails to Quell Alzheimer’s in Novo Nordisk Trials

3 months / nytimes / Gina Kolata

Tuesday, November 25, 2025, 10:21 am / permalink 16294 / 5 stories in 3 months

Novo Nordisk rolls out lower prices for Ozempic and Wegovy / Medical Express

medicalxpress - People paying out of pocket for Ozempic or Wegovy may soon see lower costs, as Novo Nordisk rolls out new price discounts for its popular GLP-1 medications.

#obesity #healthcare #pharmaceuticals #drugpricing #novonordisk #weightloss #publichealth #biotech

When Drug Price Transparency Isn’t Enough

3 months / thehealthcareblog / matthew holt

Q&A: Navigating weight loss—when to consider bariatric surgery after GLP-1 therapy

3 months / medicalxpress

Daily pill could offer alternative to weight-loss injections

3 months / newscientist

Novo Nordisk rolls out lower prices for Ozempic and Wegovy

3 months / medicalxpress

Novo Nordisk lowers self-pay prices for weight loss drugs ahead of Lilly, TrumpRx

3 months / endpoints / Zachary Brennan

Ozempic, Wegovy to be sold at $199 a month for new patients

3 months / beckershospitalreview / Paige Twenter

Thursday, November 20, 2025, 1:22 am / permalink 16131 / 6 stories in 3 months

Pfizer’s Sweeter $10B Offer Beats Novo Nordisk in Bidding War for Obesity Biotech Metsera / MedCity

Frank Vinluan / medcitynews - Pfizer’s offer of up to $86.25 in cash for each share of obesity drugs developer Metsera share tops the up to $86.20 Novo Nordisk was willing to pay. The financial consideration and the greater certainly of a deal close tipped the balance in Pfizer’s favo…

#obesity #healthcare #pharmaceuticals #novonordisk #weightloss #pfizer #biotech #mergersandacquisitions #corporatetakeover #drugdevelopment

Pfizer prevails in $10B bidding war for Metsera

4 months / beckershospitalreview / Ella Jeffries

Ex-Lilly Diabetes leaders hunt for new obesity drugs at VC firm

4 months / endpoints / Kyle LaHucik

Pfizer’s Sweeter $10B Offer Beats Novo Nordisk in Bidding War for Obesity Biotech Metsera

4 months / medcitynews / Frank Vinluan

Novo Nordisk, Pfizer make personnel waves as they squabble over Metsera

4 months / endpoints / Alex Hoffman

Monday, November 10, 2025, 12:21 am / permalink 15823 / 4 stories in 4 months

Pfizer poised to buy Metsera in $10 bn deal after bidding war / Medical Express

medicalxpress - Pfizer was poised to seal a takeover of Metsera on Saturday after its improved offer won over the biotechnology startup's board and Danish challenger Novo Nordisk called a halt to a back-and-forth bidding war.

#obesity #healthcare #pharmaceuticals #novonordisk #weightloss #pfizer #biotech #mergersandacquisitions #corporatetakeover #drugdevelopment

Pfizer poised to buy Metsera in $10 bn deal after bidding war

4 months / medicalxpress

Novo Nordisk raises Metsera bid again, hoping to top Pfizer's latest offer

4 months / endpoints / Drew Armstrong

Saturday, November 8, 2025, 3:21 pm / permalink 15805 / 2 stories in 4 months

What Trump’s New Drug Pricing Deal Means for People With Obesity / NYT

Rebecca Robbins, Dani Blum and Margot Sanger-Katz / nytimes - The president’s agreement with drug companies involves a range of prices, depending on dose, product and how you’re paying.

#trumpadministration #obesity #healthcare #pharmaceuticals #drugpricing #elililly #novonordisk #weightloss #publichealth #governmentpolicy